Replies to post #177494 on Biotech Values

[DewDiligence]

Pulmatrix reverse merges into RTGN—ticker-->‘PULM’ following reverse split:

http://finance.yahoo.com/news/ruthigen-pulmatrix-stockholders-approve-merger-200100183.html

Immediately prior to the Merger…Ruthigen will change its name to "Pulmatrix, Inc." …Immediately following the Merger, the combined company will effect a 1-for-2.5 reverse stock split of its common stock… and expects to begin trading on NASDAQ under the symbol "PULM" at the opening of trading on June 16, 2015.

…Pulmatrix is a clinical stage biotechnology company advancing a new generation of inhaled therapeutics in a novel dry powder delivery platform. The platform, called iSPERSE (inhaled small particles easily respirable and emitted), represents a new paradigm in inhaled drug delivery using particle engineering to create dry powders with unique properties: aerodynamically small, dense particles with highly efficient dispersibility and delivery to the airways. The iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance. Pulmatrix is advancing a pipeline of products including PUR0200, a once daily inhaled bronchodilator for chronic obstructive pulmonary disease, and PUR1900, an inhaled anti-infective for the treatment of cystic fibrosis. Both PUR0200 and PUR1900 are developed using Pulmatrix's iSPERSE technology.